Anti-TNF therapy of ankylosing spondylitis in clinical
practice. Results from the Czech national registry ATTRA

J 2009

Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA

PAVELKA, Karel; Šárka FOREJTOVÁ; Jiří ŠTOLFA; Karel CHROUST; Lucie BUREŠOVÁ et al.

Základní údaje

Originální název

Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA

Autoři

PAVELKA, Karel; Šárka FOREJTOVÁ; Jiří ŠTOLFA; Karel CHROUST; Lucie BUREŠOVÁ; Heřman MANN a Jiří VENCOVSKÝ

Vydání

Clinical and Experimental Rheumatology, 2009, 0392-856X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.396

Označené pro přenos do RIV

Organizační jednotka

Lékařská fakulta

UT WoS

000274264700011

Klíčová slova anglicky

Ankylosing spondylitis; anti-TNF therapy

Změněno: 26. 1. 2011 12:16, RNDr. Daniel Jakubík

Anotace

V originále

OBJECTIVES: To estimate efficacy, safety and adherence to therapy of ankylosing spondlitis (AS) patients included in the Czech National Registry ATTRA, and to look for predictive factors for therapy discontinuation.METHODS:Patients were included according to the guidelines of the Czech Society for Rheumatology, which involve failure of previous therapy, BASDAI >4, and CRP >10 mg/l. Only patients with anti-TNF administered for the first time were analysed. Adherence to therapy was evaluated using Kaplan-Meier analysis and results were presented as cumulative survival. Comparison with data on patients with rheumatoid arthritis (RA) followed in the same registry was made.RESULTS:310 of AS patients who had reached at least 1 year as well as those who discontinued the treatment before this time point were analysed. Drug survival was longer in patients with AS than in those with RA: 84% vs. 78% and 72% vs. 49% after 1 and 3 years of treatment. Significant risk factors for treatment discontinuation were female gender (RR 2.22, p=0.001) and CRP (RR 1.33, p=0.025). The proportion of patients with BASDAI <4 during the treatment period was higher in the etanercept group than in the infliximab group (p<0.001). The number of patients fully employed increased in the whole group from 48% to 63% after 1 year of treatment.CONCLUSION:Follow-up of patients with AS in the national registry shows that it is an effective and safe way of treatment with longer adherence to anti-TNF therapy in comparison with RA patients.

Citovat

PAVELKA, Karel; Šárka FOREJTOVÁ; Jiří ŠTOLFA; Karel CHROUST; Lucie BUREŠOVÁ; Heřman MANN a Jiří VENCOVSKÝ. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clinical and Experimental Rheumatology. 2009, roč. 27, č. 6, s. 964-69, 1000 s. ISSN 0392-856X.

@article{874325,
   author = {Pavelka, Karel and Forejtová, Šárka and Štolfa, Jiří and Chroust, Karel and Burešová, Lucie and Mann, Heřman and Vencovský, Jiří},
   article_number = {6},
   keywords = {Ankylosing spondylitis; anti-TNF therapy},
   language = {eng},
   issn = {0392-856X},
   journal = {Clinical and Experimental Rheumatology},
   title = {Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA},
   volume = {27},
   year = {2009}
}

TY  - JOUR
ID  - 874325
AU  - Pavelka, Karel - Forejtová, Šárka - Štolfa, Jiří - Chroust, Karel - Burešová, Lucie - Mann, Heřman - Vencovský, Jiří
PY  - 2009
TI  - Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA
JF  - Clinical and Experimental Rheumatology
VL  - 27
IS  - 6
SP  - 964-69
EP  - 964-69
SN  - 0392856X
KW  - Ankylosing spondylitis
KW  - anti-TNF therapy
N2  - OBJECTIVES: To estimate efficacy, safety and adherence to therapy of ankylosing spondlitis (AS) patients included in the Czech National Registry ATTRA, and to look for predictive factors for therapy discontinuation.METHODS:Patients were included according to the guidelines of the Czech Society for Rheumatology, which involve failure of previous therapy, BASDAI >4, and CRP >10 mg/l. Only patients with anti-TNF administered for the first time were analysed. Adherence to therapy was evaluated using Kaplan-Meier analysis and results were presented as cumulative survival. Comparison with data on patients with rheumatoid arthritis (RA) followed in the same registry was made.RESULTS:310 of AS patients who had reached at least 1 year as well as those who discontinued the treatment before this time point were analysed. Drug survival was longer in patients with AS than in those with RA: 84% vs. 78% and 72% vs. 49% after 1 and 3 years of treatment. Significant risk factors for treatment discontinuation were female gender (RR 2.22, p=0.001) and CRP (RR 1.33, p=0.025). The proportion of patients with BASDAI <4 during the treatment period was higher in the etanercept group than in the infliximab group (p<0.001). The number of patients fully employed increased in the whole group from 48% to 63% after 1 year of treatment.CONCLUSION:Follow-up of patients with AS in the national registry shows that it is an effective and safe way of treatment with longer adherence to anti-TNF therapy in comparison with RA patients.
ER  -

PAVELKA, Karel; Šárka FOREJTOVÁ; Jiří ŠTOLFA; Karel CHROUST; Lucie BUREŠOVÁ; Heřman MANN a Jiří VENCOVSKÝ. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. \textit{Clinical and Experimental Rheumatology}. 2009, roč.~27, č.~6, s.~964-69, 1000 s. ISSN~0392-856X.

Přehled o publikaci